RxDoctor Payments Data

David Carpenter, MD

Family Medicine · Ormond Beach, FLNPI 1164573192

Payments from drug & device makers

$518,373in general payments, 2019–2025

Across 500 payments — averaging $1036.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$100K
  • Lexicon Pharmaceuticals, Inc.$97K
  • AstraZeneca$89K
  • Acrotech Biopharma Inc.$87K
  • Teva Pharmaceuticals USA, Inc.$80K
  • Novo Nordisk AS$55K
  • plus $10K from 36 others

What the payments were for

  • Consulting fees$50%
  • Food & beverage$6,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518,373 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$400,821
Medicare patients
720
Services billed
11,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$119,415
XareltoRivaroxaban71$65,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$56,285
OzempicSemaglutide44$48,983
JardianceEmpagliflozin19$32,628
EntrestoSacubitril/Valsartan21$24,357
Bydureon BciseExenatide Microspheres13$21,866
MyrbetriqMirabegron19$20,133
FarxigaDapagliflozin Propanediol12$18,689
JanuviaSitagliptin Phosphate20$15,922
Breo ElliptaFluticasone/Vilanterol21$11,526
Repatha SureclickEvolocumab15$8,041
VascepaIcosapent Ethyl13$7,044
Albuterol Sulfate HfaAlbuterol Sulfate241$6,677
Gabapentin240$6,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$578$119,415110 claims
GSKTrelegy Ellipta, Breo Ellipta$99,752$67,81259 claims
Johnson & JohnsonXarelto$14$65,20271 claims
Novo NordiskOzempic$652$48,98344 claims
Boehringer IngelheimJardiance, Stiolto Respimat$85$39,05231 claims
Astellas Pharma US IncMyrbetriq$408$20,13319 claims
AstraZenecaFarxiga$89,271$18,68912 claims
MerckJanuvia$112$15,92220 claims
AbbVieSynthroid$589$5,80293 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →